Floatz logo

Desloratadine

Primary Progressive Multiple Sclerosis

Hoffmann-La RocheSmall moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Primary Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Ocrelizumab
Indapta Therapeutics, INC.
Phase 4BBB
Fampridine
University College Dublin
Phase 4BBB
Rituximab
Rigshospitalet, Denmark
Phase 3B
Dexasone
Hoffmann-La Roche
Phase 3B
DIPHENHYDRAMINE
Hoffmann-La Roche
Phase 3B

View all 45 →

Same molecule, other indications

Desloratadine is also rated in:

relapsing-remitting multiple sclerosisActive
B
Indicative · Phase 3
60 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative · Phase 2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →